Vanderbilt Translational and Clinical Cardiovascular Research Center, Vanderbilt University Medical Center, Nashville, TN, USA; Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Atherosclerosis. 2023 Aug;379:117194. doi: 10.1016/j.atherosclerosis.2023.117194. Epub 2023 Jul 26.
Despite interest in the use of polygenic risk scores (PRS) for predicting coronary heart disease (CHD) risk, the clinical utility of PRS compared to conventional risk factors has not been demonstrated. We compared the performance of PRS with that of high-sensitivity C-reactive protein (hsCRP) in two well-established cohorts.
The study population included individuals of European ancestry free of baseline CHD from ARIC (N = 13,113) and the Framingham Offspring Study (FHS) (N = 2,696). The primary predictors included a validated PRS consisting of >6.6 million single nucleotide polymorphisms and hsCRP. The outcome was incident CHD, defined as non-fatal or fatal myocardial infarction. We compared the performance of both predictors after adjusting for the Pooled Cohort Equations in multivariable-adjusted Cox regression models. We assessed discrimination and reclassification using c-statistics and net reclassification improvement.
Incident CHD occurred in 565 ARIC and 153 FHS participants. In multivariable-adjusted models, both PRS and hsCRP were associated with incident CHD (p < 0.05 in both cohorts). In models incorporating both predictors, strengths of association were similar. For instance, in ARIC, the hazard ratio per SD increment was 1.38 (95% CI, 1.27-1.50, p = 2.94 × 10) for PRS and 1.41 (1.30-1.55, p = 3.10 × 10) for hsCRP. Neither predictor significantly increased model discrimination or net reclassification when compared with models containing the Pooled Cohort Equations alone.
In two independent cohorts, PRS performed similarly to hsCRP for the prediction of CHD risk. These findings suggest PRS does not have unique clinical utility beyond this widely-available, inexpensive measure of risk in unselected middle-aged populations.
尽管人们对多基因风险评分(PRS)预测冠心病(CHD)风险的应用很感兴趣,但与传统危险因素相比,PRS 的临床实用性尚未得到证实。我们在两个成熟的队列中比较了 PRS 与高敏 C 反应蛋白(hsCRP)的性能。
研究人群包括 ARIC(N=13113)和弗雷明汉后代研究(FHS)(N=2696)中无基线 CHD 的欧洲血统个体。主要预测指标包括一个由>660 万个单核苷酸多态性和 hsCRP 组成的经过验证的 PRS。结果是新发 CHD,定义为非致死性或致死性心肌梗死。我们在多变量调整 Cox 回归模型中调整了 Pooled Cohort Equations 后,比较了两种预测因子的性能。我们使用 c 统计量和净重新分类改善来评估区分度和重新分类。
565 名 ARIC 和 153 名 FHS 参与者发生了 CHD 事件。在多变量调整模型中,PRS 和 hsCRP 均与 CHD 事件相关(两个队列中的 p 值均<0.05)。在包含两种预测因子的模型中,关联强度相似。例如,在 ARIC 中,PRS 每增加一个标准差的风险比为 1.38(95%CI,1.27-1.50,p=2.94×10),hsCRP 为 1.41(1.30-1.55,p=3.10×10)。与仅包含 Pooled Cohort Equations 的模型相比,这两种预测因子均未显著提高模型的区分度或净重新分类。
在两个独立的队列中,PRS 对 CHD 风险的预测与 hsCRP 相似。这些发现表明,PRS 在未经选择的中年人群中,除了这种广泛可用且廉价的风险衡量标准外,其临床实用性并不独特。